Roivant Sciences (ROIV) Payables (2021 - 2026)

Roivant Sciences (ROIV) has 6 years of Payables data on file, last reported at $18.0 million in Q1 2026.

• Quarterly Payables fell 24.01% year-over-year to $18.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.0 million (down 24.01% YoY) and the FY2026 annual result came in at $18.0 million, down 24.01% from the prior year.
• Payables improved to $18.0 million in Q1 2026, from $13.3 million in the prior quarter.
• In the past five years, Payables ranged from a high of $194.6 million in Q2 2022 to a low of $11.5 million in Q2 2025.
• A 5-year average of $38.7 million and a median of $27.7 million in 2024 frame the typical range for Payables.
• Annual changes were most pronounced in 2022 — Payables jumped 1196.18% — and 2023, when it slumped 74.29%.
• Tracing ROIV's Payables over 5 years: stood at $48.0 million in 2022, then fell by 26.61% to $35.2 million in 2023, then tumbled by 32.69% to $23.7 million in 2024, then sank by 43.94% to $13.3 million in 2025, then surged by 35.41% to $18.0 million in 2026.
• The last three Payables figures came in at $18.0 million (Q1 2026), $13.3 million (Q4 2025), and $15.1 million (Q3 2025), per Business Quant data.